• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series.使用延长疗程的奈玛特韦/利托那韦成功治疗免疫缺陷患者的持续性严重严重急性呼吸综合征冠状病毒2感染：病例系列
Open Forum Infect Dis. 2023 Apr 6;10(4):ofad189. doi: 10.1093/ofid/ofad189. eCollection 2023 Apr.
2
A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir.一项多国病例系列研究，描述了使用奈玛特韦/利托那韦长疗程成功治疗由奥密克戎亚谱系引起的持续性严重急性呼吸综合征冠状病毒2感染的情况。
Open Forum Infect Dis. 2023 Dec 7;11(1):ofad612. doi: 10.1093/ofid/ofad612. eCollection 2024 Jan.
3
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.成功治疗 B 细胞急性淋巴细胞白血病患者延长疗程的瑞德西韦和奈玛特韦/利托那韦治疗的严重 2019 冠状病毒病下呼吸道疾病。
Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868.
4
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.对体液免疫受损且SARS-CoV-2持续感染的患者采用瑞德西韦与奈玛特韦/利托那韦联合抗病毒治疗。
Hematol Oncol. 2023 Dec;41(5):904-911. doi: 10.1002/hon.3206. Epub 2023 Jul 15.
5
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).尼马瑞韦/利托那韦治疗对 COVID-19 高危患者上呼吸道 SARS-CoV-2 逆转录-聚合酶链反应（SARS-CoV-2 RT-PCR）阴性转化率的影响。
Clin Infect Dis. 2023 Feb 8;76(3):e148-e154. doi: 10.1093/cid/ciac600.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
7
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后出现症状反弹的临床、病毒学和免疫学评估。
Clin Infect Dis. 2023 Feb 18;76(4):573-581. doi: 10.1093/cid/ciac663.
8
Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.免疫功能低下患者反复使用奈玛特韦/利托那韦治疗持续性 SARS-CoV-2 感染成功：一例病例报告。
Infect Dis (Lond). 2023 Aug;55(8):585-589. doi: 10.1080/23744235.2023.2223274. Epub 2023 Jun 18.
9
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
10
Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.瑞德西韦-奈玛特韦组合在 SARS-CoV-2 体外模型和一例病例报告中的协同作用。
Viruses. 2023 Jul 19;15(7):1577. doi: 10.3390/v15071577.

引用本文的文献

1
Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report.在一名有弥漫性大B细胞淋巴瘤病史的患者中，使用瑞德西韦和奈玛特韦/利托那韦成功治疗长期新冠病毒感染：一例报告
J Egypt Natl Canc Inst. 2025 Jun 30;37(1):32. doi: 10.1186/s43046-025-00291-1.
2
Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma.病例报告：一名完全接种疫苗的日本男性，患有弥漫性大B细胞淋巴瘤，正在接受利妥昔单抗和依泊妥单抗治疗，感染了持续性新冠病毒。
Front Med (Lausanne). 2025 Apr 30;12:1554100. doi: 10.3389/fmed.2025.1554100. eCollection 2025.
3
Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.奈玛特韦-利托那韦治疗后新型冠状病毒2检测呈阳性患者的临床特征及治疗效果
J Med Virol. 2025 May;97(5):e70377. doi: 10.1002/jmv.70377.
4
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.四类免疫功能低下人群中发生重症新型冠状病毒肺炎的风险：法国专家观点
Infect Dis Ther. 2025 Apr;14(4):671-733. doi: 10.1007/s40121-025-01124-3. Epub 2025 Mar 18.
5
Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.尼马曲韦/利托那韦成功治疗1例接受R-CHOP方案治疗滤泡性淋巴瘤后发生多次复发新型冠状病毒肺炎的患者
Cureus. 2025 Feb 14;17(2):e79019. doi: 10.7759/cureus.79019. eCollection 2025 Feb.
6
Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.一名滤泡性淋巴瘤和肾盂癌患者新冠病毒疾病长期不愈，从瑞德西韦序贯治疗转为莫努匹拉韦治疗成功：病例报告
Cureus. 2024 Dec 15;16(12):e75722. doi: 10.7759/cureus.75722. eCollection 2024 Dec.
7
The consequences of SARS-CoV-2 within-host persistence.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在宿主体内持续存在的后果。
Nat Rev Microbiol. 2025 May;23(5):288-302. doi: 10.1038/s41579-024-01125-y. Epub 2024 Nov 25.
8
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.免疫功能低下患者的新型冠状病毒肺炎相关肺炎：临床特征与管理方法综述
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.
9
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.美国服用其奈玛特韦/利托那韦处方的患者比例。
Infect Dis Ther. 2024 Sep;13(9):2035-2052. doi: 10.1007/s40121-024-01023-z. Epub 2024 Aug 3.
10
Testing for SARS-CoV-2: lessons learned and current use cases.SARS-CoV-2 检测：经验教训和当前应用案例。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007223. doi: 10.1128/cmr.00072-23. Epub 2024 Mar 15.

本文引用的文献

1
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.尼马曲韦/利托那韦片在大型美国医疗体系中治疗早期 COVID-19：一项基于人群的队列研究。
Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13.
2
Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".患有持续性新冠病毒感染的免疫功能低下患者：“长期感染者”综述
Curr Transplant Rep. 2022;9(4):209-218. doi: 10.1007/s40472-022-00385-y. Epub 2022 Nov 12.
3
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.成功治疗 B 细胞急性淋巴细胞白血病患者延长疗程的瑞德西韦和奈玛特韦/利托那韦治疗的严重 2019 冠状病毒病下呼吸道疾病。
Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868.
4
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
5
Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab.一名患有套细胞淋巴瘤并接受利妥昔单抗治疗的男性，在没有抗 SARS-CoV-2 抗体反应证据的情况下从严重持续性 COVID-19 中康复。
J Infect Chemother. 2022 Feb;28(2):329-332. doi: 10.1016/j.jiac.2021.11.018. Epub 2021 Nov 25.
6
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.接受B细胞耗竭疗法的患者和体液免疫缺陷状态患者的COVID-19结局：一项范围综述
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
7
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient.免疫功能低下患者中严重急性呼吸综合征冠状病毒 2 持续复制。
J Infect Dis. 2021 Jan 4;223(1):23-27. doi: 10.1093/infdis/jiaa666.

使用延长疗程的奈玛特韦/利托那韦成功治疗免疫缺陷患者的持续性严重严重急性呼吸综合征冠状病毒2感染：病例系列

Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series.

作者信息

Breeden Madison, Aitken Samuel L, Baang Ji Hoon, Gravelin Misty, Kaul Daniel R, Lauring Adam S, Petty Lindsay A, Gregg Kevin S

机构信息

Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Department of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Open Forum Infect Dis. 2023 Apr 6;10(4):ofad189. doi: 10.1093/ofid/ofad189. eCollection 2023 Apr.

DOI:10.1093/ofid/ofad189
PMID:37089775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10114524/
Abstract

Immunocompromised patients with B-cell deficiencies are at risk for prolonged symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We describe 4 patients treated for B-cell malignancies with B-cell-depleting therapies who developed persistent SARS-CoV-2 infection and had resolution of symptoms following an extended course of nirmatrelvir/ritonavir.

摘要

患有B细胞缺陷的免疫功能低下患者有感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）并出现长期症状的风险。我们描述了4例接受B细胞清除疗法治疗B细胞恶性肿瘤的患者，他们出现了持续性SARS-CoV-2感染，并在接受了较长疗程的奈玛特韦/利托那韦治疗后症状得到缓解。